Investor Presentaiton

III Key Investment Highlights 6 Robust Financial Performance Robust financial performance with double digit top line and bottom line growth Revenue | EGP mn CAGR 31% 5,439 4,302 3,361 2,535 7,372 9,134 Gross Profit | EGP mn, % CAGR 35% 8.2% 7.7% 7.2% 7.3% 6.8% 6.8% 747 565 394 307 228 172 EBITDA & Margin | EGP mn, % CAGR 39% IN 3.7% 3.1% 2.9% 2.9% 2.7% 341 2.4% 228 155 122 89 62 2012 2013 2014 2015 2016 LTM' 2012 2013 2014 2015 2016 LTM 2012 2013 2014 2015 2016 LTM Net Profit & Margin | EGP mn, % CAGR 47% 1.8% 166 1.4% 1.1% 1.0% 102 0.9% 0.9% 57 35 38 23 ROE % 41% 36% 36% 32% 32% 49% Return on Fixed Assets | % 48% 42% 42% 37% 63% 96% 2012 2013 2014 2015 2016 LTM 2012 2013 2014 2015 2016 LTM 2012 2013 2014 2015 2016 LTM ibnsinapharma (1) Oct 2016- Sep 2017; (2) Normalized figure Source: Company Management 16

View entire presentation